drugset / Trial / NCT04424693
Comparing the Incidence of Preeclampsia Between Pregnant Women Receiving Tdap Vaccinations at Week 28 or at Week 36
Phase 4
Unknown
1600 enrolled
Institute of Arthritis Research
Brigham Young University · collabLouisiana State University Health Sciences Center in New Orleans · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Preeclampsia is a significant medical condition occurring in 3-8% of pregnancies and impacts deleteriously both maternal and fetal health. An important discovery has been made by Dr Craig D Scoville showing that early Tdap vaccinations in pregnancy can reduce the incidence of preeclampsia by more than 50%. A prospective clinical research trial is proposed and urgently needed to validate this finding and thereby make a significant contribution in reducing the incidence of this common and severe complication of pregnancy.
Timeline
- Start
- 2020-12-01
- Primary completion
- 2023-10-01
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Tdap | Vaccine | — | — |